U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N3O.H3O4P
Molecular Weight 277.2142
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPRONIAZID PHOSPHATE

SMILES

OP(O)(O)=O.CC(C)NNC(=O)C1=CC=NC=C1

InChI

InChIKey=YPDVTKJXVHYWFY-UHFFFAOYSA-N
InChI=1S/C9H13N3O.H3O4P/c1-7(2)11-12-9(13)8-3-5-10-6-4-8;1-5(2,3)4/h3-7,11H,1-2H3,(H,12,13);(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C9H13N3O
Molecular Weight 179.219
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21397
Gene ID: 4128.0
Gene Symbol: MAOA
Target Organism: Homo sapiens (Human)
Target ID: P27338
Gene ID: 4129.0
Gene Symbol: MAOB
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Marsilid

Approved Use

Depression

Launch Date

1951
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
150 mg single, oral (starting)
Studied dose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unknown
Health Status: unknown
Sources:
Disc. AE: Jaundice...
AEs leading to
discontinuation/dose reduction:
Jaundice (serious)
Sources:
AEs

AEs

AESignificanceDosePopulation
Jaundice serious
Disc. AE
150 mg single, oral (starting)
Studied dose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unknown
Health Status: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The chemical approach to the control of tuberculosis.
1952 Aug 8
Effects of a hydrazine monoamine oxidase inhibitor (phenelzine) on isoproterenol-induced myocardiopathies in the rat.
1967 Sep
Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.
1984 Apr
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.
1985 Sep-Oct
[Depression in the elderly. Medical treatment].
2001 Feb 24
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Patents

Sample Use Guides

50 patients with depression who had been considered suitable for E.C.T. were given iproniazid in doses up to 450 mg/day for periods varying from two to forty weeks.
Route of Administration: Oral
In Vitro Use Guide
MItochondrial fractions were isolated from bovine tissue homogenates of bovine brain and suspended in 0.1 M phosphate buffer (pH 7.4). Mitochondrial fractions were pre-incubated with 5-HT (1 mM), 2-phenylethylamine (0.8 mM), tyramine (3.2 mM), dopamine (3 mM) or Hi (10 mM) at 37 deg-C for 30 - 45 minutes. Bovine mitochondrial were further incubated with increasing concentrations of Iproniazid (0.001 to 0.1 mM) which caused gradual inhibition of the deamination of 5-HT, tyramine, and dopamine. At 1 mM of Iproniazid, there was a marked increase in HDA, which was quite small in the mitochondria not treated with Iproniazid. Treatment of bovine brain mitochondria with 1 mM Iproniazid did not induce the appearance of HDA if the catalytic sites of the MAO-A were blocked by clorgyline. A selective inhibitor of the MAO-B deprenyl did not prevent the appearance of HDA after treatment with Iproniazid.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:10:54 GMT 2023
Edited
by admin
on Fri Dec 15 18:10:54 GMT 2023
Record UNII
8DE00V62TV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IPRONIAZID PHOSPHATE
MART.   MI   WHO-DD  
Common Name English
NSC-81850
Code English
ISONICOTINIC ACID 2-ISOPROPYLHYDRAZIDE PHOSPHATE SALT
Common Name English
IPRONIAZID PHOSPHATE [MI]
Common Name English
IPRONIAZID PHOSPHATE [MART.]
Common Name English
Iproniazid phosphate [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
9367
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
FDA UNII
8DE00V62TV
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-164-1
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
DRUG BANK
DBSALT002894
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
CAS
305-33-9
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
MERCK INDEX
m6392
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY Merck Index
NSC
81850
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
SMS_ID
100000128453
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
EVMPD
SUB35494
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID20952815
Created by admin on Fri Dec 15 18:10:54 GMT 2023 , Edited by admin on Fri Dec 15 18:10:54 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY